Amygdala Neurosciences, Inc., a San Francisco, CA-based company developing pharmacotherapies to address need associated with substance use disorder, raised $5.6m in funding.
The company intends to use the funds to conduct Phase 2 clinical studies to assess ANS-6637 as a treatment for opioid, alcohol, and smoking/nicotine use disorders.
The development of its lead compound ANS-6637 is also supported by the appointment of Dr. Mack Mitchell, a current member of the Amygdala Board of Directors, to also serve as the Amygdala Chief Medical Officer (CMO).
Dr. Mitchell brings over two decades of leadership in the field of basic and clinical addiction research. His experience includes serving as the Executive Vice President of Health System at the University of Texas Southwestern Medical Center; Chief of Gastroenterology and the Medical Director of Ambulatory Services at Johns Hopkins Bayview Medical Center; the Chairman of Internal Medicine at Carolinas Medical Center; a member of numerous NIH study sections, councils and committees; and a recipient of NIH/NIAAA awards for addiction research.
The company is led by Dr. Lou Lange, co-founder and Executive Chairman of the Board.